TrialScope Launches Free EudraCT Results Conversion Service
TrialScope, a clinical trial transparency and compliance solutions provider, announced the availability of Convert, a free online clinical trial data conversion service.
TrialScope, a clinical trial transparency and compliance solutions provider, announced the availability of Convert, a free online clinical trial data conversion service. The complimentary service enables users to reuse clinical trial results data that was previously reported to the U.S. registry (clinicaltrials.gov) and convert it to the appropriate format for submission to the European registry (EudraCT).
Sponsors reporting results in Europe will need to have eligible clinical trials that ended between July 21, 2013 and July 21, 2014, to post results by July 21, 2015. Sponsors can gain access to the free conversion service from the TrialScope website at convert.trialscope.com.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
